Safety and efficacy of crenezumab in cognitively unimpaired carriers of the PSEN1Glu280Ala mutation at risk for autosomal-dominant Alzheimer's disease in Colombia (API ADAD Colombia Trial): a phase 2, randomised, double-blind, placebo-controlled trial
Pierre N. Tariot, Francisco S Lopera, Silvia Ríos-Romenets, Kaycee M. Sink et autres